Pan-Asia Index Rebalances/ Events/ Delta One, Periscope Analytics

Brian Freitas

Pan-Asia Index Rebalances/ Events/ Delta One

Periscope Analytics

Periscope Analytics focuses on event-driven trades across Asia Pacific and provides comprehensive, timely and systematic coverage of index changes to major Asia Pacific indices in a structured manner.

The analysis includes forecasted inclusions and exclusions to all major Asian indices that have significant amount of tracking assets, including estimates of passive buy/sell flow on the stocks. The service also provides commentary and impact of market consultations, ground rule changes, and other events (IPOs, spin-offs, M&A) that could lead to index changes and passive flow.

Periscope Analytics works with multi-strategy hedge funds, proprietary trading firms, stat arb trading groups and long-only investors that invest and trade in the Asia Pacific region with the data being used to trade index rebalances, avoid pre-positioning and passive flow, and to time entry into and exit from stocks.

Event-Driven Trades Across Asia Pacific

Index Rebalance

<ul>
<li>The changes to a global index in August will be announced pre-market open Thursday and will be implemented at the close of trading on 31 August.</li>
<li>The big market moves since the last rebalance result in many changes with the final number dependent on the day picked to compute market cap and free float market cap.</li>
<li>The forecast adds have outperformed the forecast deletes over the last 1, 2 and 3 months but near-term performance has been far from awesome due to the momentum unwind.</li>
</ul>


The changes to a global index in August will be announced pre-market open Thursday and will be implemented at the close of trading on 31 August.
The big market moves since the last rebalance result in many changes with the final number dependent on the day picked to compute market cap and free float market cap.
The forecast adds have outperformed the forecast deletes over the last 1, 2 and 3 months but near-term performance has been far from awesome due to the momentum unwind.


Global Index: Potential Changes in August for Asia Pac

Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

<ul>
<li>Australia's ASIC releases the aggregated short position data four business days after the reporting day. Data in this insight is up to 22nd June, published on the 26th June.</li>
<li>The largest industry net increase in the past week was A$0.4bn into "Steel"; the largest industry net decrease was A$1.9bn out of "Diversified Metals". Net shorts declined A$1.3bn week-on-week.</li>
<li>Companies mentioned in this regular weekly report include: <a href="https://www.smartkarma.com/entities/csl-ltd" target="_blank" data-smartkarma-citation="entities:917:1" rel="noopener">CSL (CSL AU)</a>, <a href="https://www.smartkarma.com/entities/cochlear-ltd" target="_blank" data-smartkarma-citation="entities:918:1" rel="noopener">Cochlear (COH AU)</a>, <a href="https://www.smartkarma.com/entities/aristocrat-leisure-ltd" target="_blank" data-smartkarma-citation="entities:10303:1" rel="noopener">Aristocrat Leisure (ALL AU)</a>, <a href="https://www.smartkarma.com/entities/bhp-group-ltd" target="_blank" data-smartkarma-citation="entities:147:1" rel="noopener">BHP (BHP AU)</a>,<a href="https://www.smartkarma.com/entities/rio-tinto-ltd" target="_blank" data-smartkarma-citation="entities:13:1" rel="noopener">Rio (RIO AU)</a>, and <a href="https://www.smartkarma.com/entities/guzman-y-gomez-limited" target="_blank" data-smartkarma-citation="entities:43656:1" rel="noopener">Guzman Y Gomez (GYG AU)</a>.</li>
</ul>


Australia's ASIC releases the aggregated short position data four business days after the reporting day. Data in this insight is up to 22nd June, published on the 26th June.
The largest industry net increase in the past week was A$0.4bn into "Steel"; the largest industry net decrease was A$1.9bn out of "Diversified Metals". Net shorts declined A$1.3bn week-on-week.
Companies mentioned in this regular weekly report include: CSL (CSL AU), Cochlear (COH AU), Aristocrat Leisure (ALL AU), BHP (BHP AU),Rio (RIO AU), and Guzman Y Gomez (GYG AU).


Aussie Shorts [22 June 2026]: CSL, Cochlear, Aristocrat Leisure, BHP, Rio, Guzman Y Gomez

Financial News, Analysis and Data, FNArena

FNArena

Financial News, Analysis and Data

Online financial media company focused on Australian equities, with a global perspective

Equity Bottom-Up

<ul><li>Cochlear&rsquo;s shock downgrade has challenged the long-held assumption the company is immune to economic cycles.</li><li> Cochlear slashed FY26 profit guidance by -30% Multiple factors disrupted growth in recent months Most concerning is falling developed market demand Analysts now question their previous assumptions</li></ul>

Cochlear&rsquo;s shock downgrade has challenged the long-held assumption the company is immune to economic cycles. Cochlear slashed FY26 profit guidance by -30% Multiple factors disrupted growth in recent months Most concerning is falling developed market demand Analysts now question their previous assumptions

Cochlear's Shock Downgrade Raises Concerns

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>
<a href="https://www.smartkarma.com/entities/cochlear-ltd" target="_blank" data-smartkarma-citation="entities:918:1" rel="noopener">Cochlear Ltd (COH AU)</a> reported modest revenue growth, gross margin contraction, and net profit decline in H1FY26, leading to ~30% correction in share price.</li>
<li>Cochlear expects stronger H2 and reiterated full-year guidance. As majority of Nexa contract renewals have been secured alongside modest price increases, the company is poised for accelerated growth ahead.</li>
<li>Cochlear shares are trading at NTM EV/EBITDA of 17.0x, well below five-years average. Cochlear can be a good defensive as well as value buying opportunity amid the U.S.-Iran war.</li>
</ul>



Cochlear Ltd (COH AU) reported modest revenue growth, gross margin contraction, and net profit decline in H1FY26, leading to ~30% correction in share price.
Cochlear expects stronger H2 and reiterated full-year guidance. As majority of Nexa contract renewals have been secured alongside modest price increases, the company is poised for accelerated growth ahead.
Cochlear shares are trading at NTM EV/EBITDA of 17.0x, well below five-years average. Cochlear can be a good defensive as well as value buying opportunity amid the U.S.-Iran war.


Cochlear Ltd (COH AU): Shares Pullback to COVID Lows; What’s Next?

Thematic (Sector/Industry)

<ul>
<li>Fosun Pharmaceutical initiated Phase 2 trial of FXS7553 for COPD in China. CSPC Pharma’s mpox mRNA vaccine candidate obtained clinical trial approval from the FDA.</li>
<li>Akeso secured NMPA approval for ivonescimab, in combination with chemotherapy, for the treatment of first-line squamous non-small cell lung cancer (sq-NSCLC). This indication marks ivonescimab’s third major approval.</li>
<li>Daiichi Sankyo’s Enhertu got China approval for the first-line treatment of breast cancer. Peptidream marked a milestone following the initiation of Phase 1 study for two radioligand therapies by Novartis.</li>
</ul>


Fosun Pharmaceutical initiated Phase 2 trial of FXS7553 for COPD in China. CSPC Pharma’s mpox mRNA vaccine candidate obtained clinical trial approval from the FDA.
Akeso secured NMPA approval for ivonescimab, in combination with chemotherapy, for the treatment of first-line squamous non-small cell lung cancer (sq-NSCLC). This indication marks ivonescimab’s third major approval.
Daiichi Sankyo’s Enhertu got China approval for the first-line treatment of breast cancer. Peptidream marked a milestone following the initiation of Phase 1 study for two radioligand therapies by Novartis.


APAC Healthcare Weekly (August 16) – Akeso, Fosun Pharma, CSPC Pharma, Daiichi Sankyo, Peptidream

Australia

Cochlear Limited researches, develops and markets cochlear implant systems for hearing impaired individuals.  The Company's hearing implant systems include Nucleus and Baha and are sold both domestically and internationally.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Cochlear Ltd (CHEOY US)

Global Index: Potential Changes in August for Asia Pac

The global index changes were announced using D1 as the cutoff. 99% hit rate across Asia Pacific, so no surprises. Big price changes in the stocks...

Brian Freitas

Aussie Shorts [22 June 2026]: CSL, Cochlear, Aristocrat Leisure, BHP, Rio, Guzman Y Gomez

Companies mentioned in this regular weekly report include: CSL (CSL AU), Cochlear (COH AU), Aristocrat Leisure (ALL AU), BHP (BHP AU), Rio (RIO...

David Blennerhassett

Cochlear's Shock Downgrade Raises Concerns

Cochlear’s shock downgrade has challenged the long-held assumption the company is immune to economic cycles. Cochlear slashed FY26 profit...

FNArena

Cochlear Ltd (COH AU): Shares Pullback to COVID Lows; What’s Next?

Cochlear reported modest revenue growth, margin contraction, and profit decline in H1FY26. However, the company expects stronger H2 and is poised...

Tina Banerjee

APAC Healthcare Weekly (August 16) – Akeso, Fosun Pharma, CSPC Pharma, Daiichi Sankyo, Peptidream

Akeso’s ivonescimab and Daiichi Sankyo’s Enhertu got additional indications approvals in China. CSPC Pharma’s mpox mRNA vaccine candidate got FDA...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Global Index: Potential Changes in August for Asia Pac

The global index changes were announced using D1 as the cutoff. 99% hit rate across Asia Pacific, so no surprises. Big price changes in the stocks...

Brian Freitas

Aussie Shorts [22 June 2026]: CSL, Cochlear, Aristocrat Leisure, BHP, Rio, Guzman Y Gomez

Companies mentioned in this regular weekly report include: CSL (CSL AU), Cochlear (COH AU), Aristocrat Leisure (ALL AU), BHP (BHP AU), Rio (RIO...

David Blennerhassett

Cochlear's Shock Downgrade Raises Concerns

Cochlear’s shock downgrade has challenged the long-held assumption the company is immune to economic cycles. Cochlear slashed FY26 profit...

FNArena

Cochlear Ltd (COH AU): Shares Pullback to COVID Lows; What’s Next?

​Cochlear reported modest revenue growth, margin contraction, and profit decline in H1FY26. However, the company expects stronger H2 and is poised...

Tina Banerjee

APAC Healthcare Weekly (August 16) – Akeso, Fosun Pharma, CSPC Pharma, Daiichi Sankyo, Peptidream

Akeso’s ivonescimab and Daiichi Sankyo’s Enhertu got additional indications approvals in China. CSPC Pharma’s mpox mRNA vaccine candidate got FDA...

Tina Banerjee

Cochlear reported modest revenue growth, margin contraction, and profit decline in H1FY26. However, the company expects stronger H2 and is poised...